Technology
Health
Pharmaceutical

Pacira Pharmaceuticals

$39.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.08 (-2.65%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PCRX and other stocks, options, ETFs, and crypto commission-free!

About

Pacira Pharmaceuticals, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Read More The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Employees
518
Headquarters
Parsippany, New Jersey
Founded
2006
Market Cap
1.68B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
679.39K
High Today
$41.14
Low Today
$39.61
Open Price
$40.79
Volume
197.94K
52 Week High
$55.00
52 Week Low
$26.95

Collections

Technology
Health
Pharmaceutical
US
North America

News

MarketWatchMar 8

Pacira Pharmaceuticals Inc.

Shares of Pacira Pharmaceuticals Inc. fell 1.9% in premarket trade Tuesday after the company announced it was planning to acquire MyoScience Inc., a privately-held company that markets an FDA-approved non-opioid treatment for pain associated with osteoarthritis and knee replacement surgery. MyoScience's therapy, called Iovera, is a device that delivers doses of cold temperature to targeted nerves, which temporarily stops those nerves from sending pain signals -- a technique known as cryoanalgesia. Pacira th...

41
Seeking AlphaFeb 28

Pacira Pharmaceuticals beats by $0.20, beats on revenue

Pacira Pharmaceuticals (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.47 beats by $0.20; GAAP EPS of $0.20 beats by $0.14. Revenue of $95.12M (+20.3% Y/Y) beats by $1.41M . Press Release...

53
Seeking AlphaFeb 27

Pacira Pharmaceuticals Q4 Earnings Preview

Pacira Pharmaceuticals (NASDAQ:PCRX) is scheduled to announce Q4 earnings results on Thursday, February 28th, before market open.

31

Earnings

-$0.11
$0.08
$0.28
$0.47
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.